Assessment of platelet function in acute ischemic stroke patients previously treated with aspirin

Journal of Stroke and Cerebrovascular Diseases

Volumn 23, Issue 10, 2014, Pages 2794-2799

  Lago, Aida ^a   Parkhutik, Vera ^a   Tembl, Jose Ignacio ^a   Vallés, Juana ^a   Santos, Maria Teresa ^a   Moscardó, Antonio ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Antiplatelet; Aspirin; Clopidogrel; Ischemic stroke

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYSINE ACETYLSALICYLATE; THROMBOXANE A2; VASODILATOR AGENT; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; TICLOPIDINE;

ADD ON THERAPY; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN ISCHEMIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RISK FACTOR; RISK REDUCTION; STROKE PATIENT; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER; TIME; TRANSIENT ISCHEMIC ATTACK; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; STROKE; THROMBOCYTE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; BRAIN ISCHEMIA; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; STROKE; THROMBOXANE A2; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923229193     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2014.07.007     Document Type: Article

References (25)

1. Pendlebury ST, Rothwell PM. Risk of recurrent stroke, other vascular events and dementia after transient ischaemic attack and stroke. Cerebrovasc Dis 2009;27(Suppl 3):1-11.
2. Grundmann K, Jaschonek K, Kleine B, et al. Aspirin nonresponder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003;250:63-66.
3. Hohlfeld T,Weber AA, Junghans U, et al. Variable platelet response to aspirin in patients with ischemic stroke. Cerebrovasc Dis 2007;24:43-50.
4. Meves SH, Overbeck U, Endres HG, et al. Dose-dependent effect of early antiplatelet therapy in acute ischaemic stroke. Thromb Haemost 2012;107:69-79.
5. Richard S, Toussaint-Hacquard M, Fay R, et al. Laboratory effect on platelet activity within 24 h of the first 300-mg oral dose of aspirin given in hospital during the acute phase of ischemic cerebral events. Cerebrovasc Dis 2012;33:574-578.
6. Breet NJ, van Werkum JW, Bouman HJ, et al. High onaspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost 2010; 8:2140-2148.
7. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655.
8. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot study including 180 post-stroke patients. Thromb Res 1993;71:397-403.
9. Schwammenthal Y, Tsabari R, Shenkman B, et al. Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome. Cerebrovasc Dis 2008;25:355-361.
10. Valles J, Lago A, Moscardó A, et al. TXA2 synthesis and COX1-independent platelet reactivity in aspirin-treated patients soon after acute cerebral stroke or transient ischaemic attack. Thromb Res 2013;132:211-216.
11. Alberts MJ. Platelet function testing for aspirin resistance is reasonable to do: yes!. Stroke 2010;41:2400-2401.
12. Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008;133:630S-669S.
13. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38:1655-1711.
14. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008;39:1647-1652.
15. Santos MT, Valles J, Lago A, et al. Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease. J Thromb Haemost 2008;6:615-621.
16. Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998;97:350-355.
17. Serena J, Dávalos A, Segura T, et al. Stroke on awakening: looking for a more rational management. Cerebrovasc Dis 2003;16:128-133.
18. Lago A, Tembl JI, Pareja A, et al. Adherence to aspirin in secondary prevention of ischemic stroke. Cerebrovasc Dis 2006;21:353-356.
19. Fares RR, Lansing LS, Gallati CA, et al. Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination. Expert Opin Pharmacother 2008;9:377-386.
20. Furie KL, Kasner SE, Adams RJ, et al, on behalf of the American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227-276.
21. O'Donnell MJ, Hankey GJ, Eikelboom JW. Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke: a critical review. Stroke 2008; 39:1638-1646.
22. Kennedy J, Hill MD, Ryckborst KJ, et al. The Fast Assessment of Stroke and Transient ischemic attack to prevent Early Recurrence (FASTER) trial: a pilot randomised controlled trial. Lancet Neurol 2007;6:961-969.
23. Wang Y, Wang Y, Zhao X, et al, for the CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11-19.
24. Qureshi AI, Luft AR, Sharma M, et al. Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures. Neurosurgery 2000;46:1344-1359.
25. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-2494.